Executive Summary
Abbott's launch of the 1,000-patient TREAT TR post-market study converts TriClip from a trial-validated device into a mandatory real-world evidence generator, arriving weeks after ESC 2025 elevated transcatheter tricuspid intervention to Class IIa and days after a first-in-human ARCTIC-T report in Structural Heart described using T-TEER to pre-condition the annulus for subsequent TTVR. A Chinese single-center retrospective in Journal of Clinical Medicine reported equivalent 5-year composite outcomes between TAVR and SAVR in patients under 75 (45.9% vs 43.4%, weighted HR 1.00), including a BAV subgroup, but a baseline age imbalance of 11 years (67.9 vs 56.5) makes any read across to guideline-relevant populations invalid. The OCEAN-Mitral registry (N=3,511) identified baseline CRP as an independent predictor of death after M-TEER (HR 1.98), which sharpens patient selection now that ESC 2025 has upgraded TEER for ventricular SMR to Class I.
- ESC-relevant: OCEAN-Mitral shows CRP >3.0 mg/L plus temperature ≥37°C identifies the highest-risk M-TEER phenotype, adding a cheap biomarker to the COAPT selection framework (JAHA).
- A single-center TAVR series (N=408) found post-procedural BNP at day 2 outperformed baseline BNP for predicting cardiac events (c-statistic 0.75 vs 0.64) (Int J Cardiol).
- Medtronic's Intrepid TTVR pivotal trial (NCT07321899) is recruiting 1,186 patients head-to-head against the Edwards EVOQUE — the first randomized TTVR-vs-TTVR comparison.
- A TriNetX propensity-matched analysis (N=421 pairs) linked tirzepatide use after TAVR to lower 1-year HF (HR 0.68) and AKI (HR 0.63) in obese patients; residual confounding is high and the falsification endpoint (falls) trended in the same direction as the primary.
- Edwards reported TMTT revenue +47% growth, and UBS initiated coverage with a Buy — TMTT is now the growth thesis, not TAVR.
What to watch: Boston Scientific reports Q2 earnings tomorrow (July 29) with EPS estimate $0.83 and revenue $5.37B — Acurate Neo commentary and any WATCHMAN/structural pipeline update will move the sector.
Aortic Valve (TAVR/TAVI)
A retrospective Chinese single-center series (N=1,646, 2014–2023) claims 5-year equipoise between TAVR and SAVR in patients under 75, but the data don't survive scrutiny. In the Journal of Clinical Medicine report, TAVR patients were 11 years older at baseline (67.9 vs 56.5) with higher STS scores; even after IPTW, the composite of death/stroke/CV rehospitalization landed at 45.9% vs 43.4% (weighted HR 1.00). ESC 2025 recommends SAVR for patients under 70 at low surgical risk (Class I); ACC/AHA 2020 recommends SAVR under 65 (Class I) — both citing BAV anatomy and long-term durability as the primary rationale. This paper does not move either position. In the BAV subgroup (N=516), 5-year mortality was numerically 2.4× higher with TAVR (8.3% vs 3.4%, p=0.349) — statistically null in a subgroup almost certainly underpowered, and directionally consistent with what the guidelines predict. A separate narrative review of TAVR in patients ≤65 in Life reinforces the same point: no RCT exists for this age group, and observational cohorts show heavier comorbidity burdens than age-matched SAVR recipients — real-world TAVR under 65 is happening in sicker patients, not equivalent ones.
The BNP kinetics study from a Japanese TAVR cohort (N=408) offers a more actionable finding: post-procedural BNP at day 2 outperformed baseline BNP for predicting cardiac events (c-statistic 0.75 vs 0.64, p=0.03). Combined with the integrated PPMI + cardiac damage scoring from a Chinese cohort (N=1,274) showing worst survival in patients with both PPMI and advanced cardiac damage (HR 2.98), the field is converging on multi-parameter post-TAVR risk stratification. The tirzepatide-TAVR TriNetX analysis is non-randomized, and the falsification endpoint (falls) trended in the same direction as the primary — residual confounding by health-seeking behavior is the most plausible explanation.
Mitral Valve (MitraClip, PASCAL, TMVR)
The OCEAN-Mitral registry identified a cheap, universally available biomarker that risk-stratifies M-TEER candidates where COAPT could not. In 3,511 patients, baseline CRP >3.0 mg/L independently predicted death (HR 1.98, 95% CI 1.63–2.40), with additive risk when combined with body temperature ≥37°C. This is a Japanese registry, observational, and weighted toward mixed DMR and functional MR populations — but the signal survived sequential Cox adjustment for clinical, laboratory, and echocardiographic covariates. ESC 2025 upgraded TEER for ventricular SMR to Class I (from ACC/AHA 2020 Class IIa), and the guidelines' COAPT-derived selection criteria (LVEF 20–50%, LVESD ≤70mm, SPAP ≤70mmHg) do not include inflammation. Adding CRP screening would tighten patient selection at essentially zero cost.
A related explanted-heart pathology report in Structural Heart offers a rare ventricular-side view of MitraClip integration into leaflets and chordae — the authors flag potential biomechanical consequences for long-term TEER durability, an argument that aligns with the surgical community's ongoing durability concerns. On primary MR, the ESC 2025 review of MR management in Biomedicines reiterates that surgical repair remains preferred — ESC 2025 has upgraded early repair in asymptomatic PMR with 3+ risk factors (AF, SPAP >50mmHg, LA dilation, concomitant TR) to Class I, a more aggressive posture than ACC/AHA 2020's Class IIa recommendation. TEER for primary MR remains Class IIa under both guidelines, reserved for high-risk symptomatic patients with suitable anatomy.
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] Abbott's TREAT TR post-market study will enroll ~1,000 patients across up to 100 sites in the US, Canada, and Europe with follow-up to 5 years. This is the real-world evidence layer that ESC 2025's Class IIa transcatheter TR recommendation demanded — TRILUMINATE Pivotal and Tri.Fr showed QoL and HF-hospitalization benefit but no mortality signal, and the surgical community (Chikwe, Badhwar) has pointed out that TR TEER trials excluded RV dysfunction, pre-capillary PH, and advanced HF. ESC 2025 elevated TV surgery for symptomatic severe primary TR to Class I (from ACC/AHA 2020 Class IIa); transcatheter TR treatment sits at Class IIa, explicitly restricted to patients without severe RV dysfunction or pre-capillary PH. TREAT TR data at 30 days, 6 months, and annually to 5 years will determine whether the trial signal holds in less-selected patients — and whether the boundaries ESC drew around the Class IIa indication reflect real clinical biology or trial selection artifact.
The ARCTIC-T concept in Structural Heart — first-in-human use of T-TEER to cinch the annulus prior to TTVR — is hypothesis-generating (N=1), but reflects a real emerging problem: TTVR devices need anchoring geometry that many severe TR annuli cannot provide. Medtronic's Intrepid TTVR pivotal trial (NCT07321899, N=1,186 recruiting) is the first head-to-head TTVR-vs-TTVR study (Intrepid vs Edwards EVOQUE), and the 15.9% new pacemaker rate reported for EVOQUE in the STS/ACC TVT registry sets a durability-of-utility bar Intrepid must beat. Isolated tricuspid surgery contemporary mortality has fallen with earlier referral; the Innsbruck endoscopic mitral+tricuspid case report in dextrocardia/scimitar syndrome illustrates that experienced centers can execute complex TV repair in anatomy where transcatheter is not feasible. The referral pipeline, not the technology, remains the gating factor for both surgical and transcatheter tricuspid therapy.
Surgical vs. Transcatheter Comparisons
The Chinese under-75 TAVR-vs-SAVR retrospective claims equipoise but is not a randomized trial and does not address the durability question that drives current guidelines. Under ACC/AHA 2020, SAVR remains Class I under 65 on durability grounds; ESC 2025 raised that threshold to 70 based on DEDICATE and longer-term PARTNER 3/Evolut LR follow-up, but explicitly noted patients under 70 are poorly represented in RCTs. The paper's under-75 BAV subgroup shows numerically higher TAVR mortality — the direction both guidelines predict. A separate single-center PCI-after-TAVR study (N=73) reports 95% PCI success and no balloon-expandable vs self-expandable valve difference in overall outcomes, but LCX access was significantly more difficult in self-expandable valve patients (54% vs 29%, p=0.035) — a lifetime-management issue ESC 2025 explicitly flagged as a critical index-procedure planning variable when life expectancy exceeds assumed valve durability.
Device & Technology
Edwards received FDA clearance for the Ecliptis Left Atrial Appendage clip, expanding the structural franchise beyond valves. A single-center Myval vs Acurate Neo comparison (N=147) reported comparable mid-term outcomes but higher mild PVL with Acurate Neo (38.7% vs 20.6%, p=0.038) — consistent with the LANDMARK trial's noninferiority conclusion for Myval. A Myval balloon rupture case report describes a propofol-as-lubricant bailout for balloon extraction. That case and the TAVR migration after valve-sparing root replacement report are reminders that off-label TAVR anatomies remain hazardous.
Regulatory & Policy
No new US or EU regulatory actions today beyond the Ecliptis clearance noted above. Abbott's TREAT TR launch is a post-market commitment tied to the 2024 TriClip PMA — a structure the FDA has deployed with increasing frequency for transcatheter tricuspid devices, where trial populations are narrow and real-world generalizability is unproven.
Industry & Market
Edwards TMTT revenue growth of +47% reframes the Edwards thesis: transcatheter mitral and tricuspid, not TAVR, is the growth vector. UBS's Buy initiation and Rothschild/Redburn's price target raise to $102 both hinge on TMTT execution and PASCAL/EVOQUE ramp. Multiple insider sales at Edwards this week (Zovighian, Markowitz, others) are Form 144/10b5-1 planned dispositions — routine, but worth flagging given current valuation pressure.
Financial Analysis
The market's read on today's news split the sector: Medtronic (+3.16%) and Abbott (+2.66%) both rallied on tricuspid device momentum (Intrepid pivotal recruiting, TREAT TR launched), while Edwards (+0.77%) lagged despite the Ecliptis clearance and UBS Buy — reflecting concern that TMTT growth won't offset TAVR maturity. Boston Scientific's collapse to $46.06 (down 50% over 6 months) is largely the WATCHMAN and CRM story rather than valve-specific, but Acurate Neo commentary in tomorrow's Q2 print will matter. Anteris (+3.04% today, +33% over 6 months) trades as a speculative TAVR pure-play on DurAVR — no clinical data expected near-term.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $83.68 (+0.77%); 6-month change: +2.69%
- Market cap: $48.2B; trailing P/E 49.51; forward P/E 24.79; beta 0.85
- 52-week range: $72.30–$96.29; analyst target $100.96 (Buy, 26 analysts)
- TMTT revenue grew 47% last quarter — PASCAL and EVOQUE ramp is the growth story; Ecliptis LAA clip FDA clearance today expands the structural franchise beyond valves. UBS initiated Buy this week; Rothschild/Redburn raised target to $102. Multiple insider Form 144 sales are 10b5-1 dispositions.
Medtronic (MDT)
- Close: $86.88 (+3.16%); 6-month change: –12.50%
- Market cap: $111.2B; trailing P/E 22.57; forward P/E 13.55; beta 0.58
- 52-week range: $73.31–$106.33; analyst target $98.44 (Buy, 25 analysts)
- Next earnings Sept 1 (EPS est $1.39, Rev est $9.55B). Intrepid TTVR pivotal (NCT07321899, N=1,186) is recruiting head-to-head against Edwards EVOQUE — the tricuspid story is the near-term catalyst. Evolut FX+ coronary access concerns after TAVR persist (see PCI-after-TAVR study).
Abbott (ABT)
- Close: $107.27 (+2.66%); 6-month change: +2.47%
- Market cap: $186.8B; trailing P/E 34.72; forward P/E 17.69; beta 0.61
- 52-week range: $81.97–$137.49; analyst target $118.42 (Buy, 24 analysts)
- Next earnings Oct 14 (EPS est $1.42, Rev est $12.99B). TREAT TR launch today (1,000 patients, 5-year follow-up) locks in TriClip's post-market evidence base and cements Abbott's tricuspid lead ahead of Intrepid pivotal readout.
Boston Scientific (BSX)
- Close: $46.06 (+1.21%); 6-month change: –50.11%
- Market cap: $68.5B; trailing P/E 19.03; forward P/E 12.41; beta 0.58
- 52-week range: $42.20–$109.50; analyst target $72.31 (Strong Buy, 29 analysts)
- Next earnings tomorrow (July 29): EPS est $0.83, Rev est $5.37B. Acurate Neo showed higher mild PVL vs Myval in today's single-center comparison — watch commentary on the platform, WATCHMAN growth, and any structural pipeline update.
Anteris Technologies (AVR.AX)
- Close: A$11.85 (+3.04%); 6-month change: +33.15%
- Market cap: A$1.2B; forward P/E –5.43; beta 0.73
- 52-week range: A$4.89–A$15.47; analyst target A$13.00 (1 analyst)
- DurAVR THV pivotal timeline remains the sole catalyst; trades as a speculative TAVR bet without a peer group.
Split sector performance — Medtronic and Abbott up on tricuspid, Edwards flat despite TMTT growth, Boston Scientific bracing for earnings — reflects investors' shift from TAVR maturity toward the mitral/tricuspid growth chapter. That is precisely the therapeutic transition ESC 2025 codified.
Clinical Trial Updates
Tricuspid Replacement
- [LANDMARK] NCT07321899 — Transcatheter Tricuspid Valve Replacement With Medtronic Intrepid TTVR System in Severe TR. RECRUITING. Enrollment: 1,186. Sponsor: Medtronic. Head-to-head vs Edwards EVOQUE — the first TTVR-vs-TTVR randomized comparison, and the trial that will determine tricuspid market share for the next decade. Last updated 2026-07-28.
Tricuspid Repair
- [LANDMARK] TREAT TR (Abbott, launched 2026-07-28) — Post-market study of TriClip in ~1,000 real-world patients at up to 100 sites across US, Canada, Europe. Follow-up through 5 years. Co-PI Anita Asgar (Northwestern Bluhm). This is the real-world evidence layer required by ESC 2025's Class IIa recommendation.
Social & Conference Highlights
The 2025 Accra Declaration on cost-effective cardiac surgery in Africa (reference literature) is the field's global-equity story in concrete form: transcatheter economics remain prohibitive across most of the continent, and the Pan-African Society's fellowship and simulation-training framework is where valve therapy access actually starts.
Tomorrow's Boston Scientific earnings and ongoing Intrepid pivotal enrollment will define the next 90 days of sector narrative. Watch for Acurate Neo commentary and any signal on Boston Scientific's tricuspid pipeline — the field has room for a third TTVR device, but the window is closing.